Financial Daily from THE HINDU group of publications
Wednesday, Feb 22, 2006
News
Features
Stocks
Shipping
Archives
Google

Group Sites

 Marketing - Channels and Franchises


Lupin snaps supply deal with US co

Our Bureau

Mumbai , Feb. 21

LUPIN has discontinued its co-promotion agreement with Cornerstone Biopharma Inc for the distribution of Lupin's antibiotic Suprax in the US.

Lupin said that its wholly owned subsidiary in the US, Lupin Pharmaceutical Inc was reorganising its sales structure following the "encouraging trend" in the sales of Suprax.

The sales force now contracted through Ventiv Health US Sales LLC will be internalised at the beginning of the next quarter, a note from the company said.

More Stories on : Channels and Franchises | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Marico forays into baby-care category

Turner International to launch two theme parks
Ficci bid to promote animation industry
ITC Foods forays into instant mix segment, dishes out 5 products
UTV's new animation facility
Ogilvy's online media division re-christened Neo@OgilvyOne
Titan Industries launches Xylys watches, plans more brands
Jealous Jeans offer for girls
Exclusive marketing rights for Novartis' cancer drug cancelled
Lupin snaps supply deal with US co
Speciality Restaurants plans new chain to revive old recipes
AFL launches `convenience services' retail chain
To offer money transfer, international telephony, e-ticketing
Rajesh Exports to go inorganic for retail foray — To buy small, medium jewellery stores
Retail talent crisis: Head-hunters combing all sectors
Pantaloon plans micro-financing schemes to woo more customers
Christian Dior opens first outlet here
Portal to search serviced apartments

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line